NDA:XETRAurubis AG Analysis
Data as of 2026-07-07 - not real-time
$84.47
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Nasdaq, Inc. is trading at $84.47, just above its 20‑day SMA of 84.02 but still below the 50‑day (87.76) and 200‑day (89.00) averages, reinforcing a bearish longer‑term bias. The RSI of 49.8 suggests neutral momentum, while the MACD histogram is positive and the MACD line sits above its signal, hinting at a short‑term bullish tilt. Volatility remains elevated at nearly 39% 30‑day and beta is modest at 0.71, indicating the stock moves less than the market but with sizable price swings. Fundamentals are strong: revenue grew 13.7% YoY, operating margins are a robust 48% and profit margins exceed 35%, and ROE sits at 16%. However, the current price implies a forward PE of 19.0, well above the industry average PE of 17.7, and the DCF‑derived fair value of $48.4 is far below market levels, flagging the stock as overvalued. The dividend yield of 1.32% with a payout ratio under 33% appears sustainable, yet the balance sheet shows a high debt‑to‑equity ratio of 79, adding leverage risk.
Overall, while Nasdaq’s growth drivers and cash‑generating capacity are compelling, the combination of elevated valuation multiples, significant debt, and heightened price volatility suggests caution. The moderate beta and low currency exposure temper risk, but sector‑specific regulatory scrutiny and the competitive landscape keep sector risk at a medium level. Investors should weigh the attractive dividend and strong operating performance against the pricing disconnect and leverage concerns when forming a view on the stock.
Overall, while Nasdaq’s growth drivers and cash‑generating capacity are compelling, the combination of elevated valuation multiples, significant debt, and heightened price volatility suggests caution. The moderate beta and low currency exposure temper risk, but sector‑specific regulatory scrutiny and the competitive landscape keep sector risk at a medium level. Investors should weigh the attractive dividend and strong operating performance against the pricing disconnect and leverage concerns when forming a view on the stock.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below 50‑day and 200‑day SMAs indicating bearish trend
- Elevated 30‑day volatility and modest beta increasing price risk
- Current price far exceeds DCF fair value, suggesting overvaluation
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong revenue growth and high operating margins
- Sustainable dividend yield with low payout ratio
- Continued leverage concerns and valuation premium to peers
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Robust cash flow generation supporting dividend sustainability
- Low beta and limited currency exposure reducing systematic risk
- High debt‑to‑equity ratio and overvalued multiples limiting upside
Key Metrics & Analysis
Financial Health
Revenue Growth13.70%
Profit Margin35.28%
P/E Ratio25.4
ROE16.20%
ROA5.55%
Debt/Equity79.06
P/B Ratio4.0
Op. Cash Flow$2.3B
Free Cash Flow$1.6B
Industry P/E17.7
Technical Analysis
TrendBearish
RSI49.8
Support$76.55
Resistance$92.75
MA 20$84.02
MA 50$87.76
MA 200$89.00
MACDBullish
VolumeIncreasing
Fear & Greed Index93.63
Valuation
Fair Value$48.41
Target Price$106.13
Upside/Downside25.65%
GradeOvervalued
TypeBlend
Dividend Yield1.32%
Risk Assessment
Beta0.71
Volatility38.86%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.